Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.70M | 2.47M | 2.25M | 6.57M | 7.10M |
| Depreciation & Amortization | 51.90K | 73.50K | 77.90K | 70.30K | 66.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.33M | 3.31M | 3.49M | 8.80M | 10.01M |
| Operating Income | -2.33M | -3.31M | -3.49M | -8.80M | -10.01M |
| Income Before Tax | -2.52M | -2.67M | -2.99M | -8.53M | -9.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.52 | -2.67 | -2.99 | -8.53 | -9.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.52M | -2.67M | -2.99M | -8.53M | -9.72M |
| EBIT | -2.33M | -3.31M | -3.49M | -8.80M | -10.01M |
| EBITDA | -2.30M | -3.26M | -3.44M | -8.75M | -9.97M |
| EPS Basic | -0.05 | -0.06 | -0.07 | -0.19 | -0.22 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.04 | -0.12 | -0.14 |
| EPS Diluted | -0.05 | -0.06 | -0.07 | -0.19 | -0.22 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.04 | -0.12 | -0.14 |
| Average Basic Shares Outstanding | 195.65M | 186.45M | 181.85M | 179.75M | 178.10M |
| Average Diluted Shares Outstanding | 195.65M | 186.45M | 181.85M | 179.75M | 178.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |